Literature DB >> 26903548

Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome.

Nicholas Hubbard1, David Hagin1, Karen Sommer1, Yumei Song1, Iram Khan1, Courtnee Clough1, Hans D Ochs2, David J Rawlings3, Andrew M Scharenberg3, Troy R Torgerson2.   

Abstract

Loss of CD40 ligand (CD40L) expression or function results in X-linked hyper-immunoglobulin (Ig)M syndrome (X-HIGM), characterized by recurrent infections due to impaired immunoglobulin class-switching and somatic hypermutation. Previous attempts using retroviral gene transfer to correct murine CD40L expression restored immune function; however, treated mice developed lymphoproliferative disease, likely due to viral-promoter-dependent constitutive CD40L expression. These observations highlight the importance of preserving endogenous gene regulation in order to safely correct this disorder. Here, we report efficient, on-target, homology-directed repair (HDR) editing of the CD40LG locus in primary human T cells using a combination of a transcription activator-like effector nuclease-induced double-strand break and a donor template delivered by recombinant adeno-associated virus. HDR-mediated insertion of a coding sequence (green fluorescent protein or CD40L) upstream of the translation start site within exon 1 allowed transgene expression to be regulated by endogenous CD40LG promoter/enhancer elements. Additionally, inclusion of the CD40LG 3'-untranslated region in the transgene preserved posttranscriptional regulation. Expression kinetics of the transgene paralleled that of endogenous CD40L in unedited T cells, both at rest and in response to T-cell stimulation. The use of this method to edit X-HIGM patient T cells restored normal expression of CD40L and CD40-murine IgG Fc fusion protein (CD40-muIg) binding, and rescued IgG class switching of naive B cells in vitro. These results demonstrate the feasibility of engineered nuclease-directed gene repair to restore endogenously regulated CD40L, and the potential for its use in T-cell therapy for X-HIGM syndrome.
© 2016 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26903548     DOI: 10.1182/blood-2015-11-683235

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity.

Authors:  Annelise G Snyder; Nicholas W Hubbard; Michelle N Messmer; Sigal B Kofman; Cassidy E Hagan; Susana L Orozco; Kristy Chiang; Brian P Daniels; David Baker; Andrew Oberst
Journal:  Sci Immunol       Date:  2019-06-21

2.  Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells.

Authors:  Malika Hale; Taylor Mesojednik; Guillermo S Romano Ibarra; Jaya Sahni; Alison Bernard; Karen Sommer; Andrew M Scharenberg; David J Rawlings; Thor A Wagner
Journal:  Mol Ther       Date:  2017-01-28       Impact factor: 11.454

3.  Site-Specific Gene Editing of Human Hematopoietic Stem Cells for X-Linked Hyper-IgM Syndrome.

Authors:  Caroline Y Kuo; Joseph D Long; Beatriz Campo-Fernandez; Satiro de Oliveira; Aaron R Cooper; Zulema Romero; Megan D Hoban; Alok V Joglekar; Georgia R Lill; Michael L Kaufman; Sorel Fitz-Gibbon; Xiaoyan Wang; Roger P Hollis; Donald B Kohn
Journal:  Cell Rep       Date:  2018-05-29       Impact factor: 9.423

Review 4.  Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome.

Authors:  Xiangxue Meng; Bin Yang; Wen-Chen Suen
Journal:  Innate Immun       Date:  2017-11-13       Impact factor: 2.680

5.  Knock-in editing: it functionally corrects!

Authors:  Matthew H Porteus
Journal:  Blood       Date:  2016-05-26       Impact factor: 22.113

Review 6.  Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned.

Authors:  Richard A Morgan; David Gray; Anastasia Lomova; Donald B Kohn
Journal:  Cell Stem Cell       Date:  2017-11-02       Impact factor: 24.633

Review 7.  The past and presence of gene targeting: from chemicals and DNA via proteins to RNA.

Authors:  T M Geel; M H J Ruiters; R H Cool; L Halby; D C Voshart; L Andrade Ruiz; K E Niezen-Koning; P B Arimondo; M G Rots
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-06-05       Impact factor: 6.237

8.  X-linked hyper-IgM syndrome complicated with interstitial pneumonia and liver injury: a new mutation locus in the CD40LG gene.

Authors:  Tian-Jiao Wang; Li-Fang Wu; Junguo Chen; Wen Zhu; Hua Wang; Xiao-Lin Liu; Yi-Qun Teng
Journal:  Immunol Res       Date:  2019-10       Impact factor: 2.829

9.  Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation.

Authors:  M Teresa de la Morena; David Leonard; Troy R Torgerson; Otavio Cabral-Marques; Mary Slatter; Asghar Aghamohammadi; Sharat Chandra; Luis Murguia-Favela; Francisco A Bonilla; Maria Kanariou; Rongras Damrongwatanasuk; Caroline Y Kuo; Christopher C Dvorak; Isabelle Meyts; Karin Chen; Lisa Kobrynski; Neena Kapoor; Darko Richter; Daniela DiGiovanni; Fatima Dhalla; Evangelia Farmaki; Carsten Speckmann; Teresa Español; Anna Shcherbina; Imelda Celine Hanson; Jiri Litzman; John M Routes; Melanie Wong; Ramsay Fuleihan; Suranjith L Seneviratne; Trudy N Small; Ales Janda; Liliana Bezrodnik; Reinhard Seger; Andrea Gomez Raccio; J David M Edgar; Janet Chou; Jordan K Abbott; Joris van Montfrans; Luis Ignacio González-Granado; Nancy Bunin; Necil Kutukculer; Paul Gray; Gisela Seminario; Srdjan Pasic; Victor Aquino; Christian Wysocki; Hassan Abolhassani; Morna Dorsey; Charlotte Cunningham-Rundles; Alan P Knutsen; John Sleasman; Beatriz Tavares Costa Carvalho; Antonio Condino-Neto; Eyal Grunebaum; Helen Chapel; Hans D Ochs; Alexandra Filipovich; Mort Cowan; Andrew Gennery; Andrew Cant; Luigi D Notarangelo; Chaim M Roifman
Journal:  J Allergy Clin Immunol       Date:  2016-09-30       Impact factor: 10.793

10.  CRISPR/Cas9 genome editing in human hematopoietic stem cells.

Authors:  Rasmus O Bak; Daniel P Dever; Matthew H Porteus
Journal:  Nat Protoc       Date:  2018-01-25       Impact factor: 13.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.